No Data
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)
Form 144 | Glaukos(GKOS.US) Director Proposes to Sell 560K in Common Stocks
SEC FILLINGS DISCLOSED/ May 30, $Glaukos(GKOS.US)$ Director Kliman Gilbert H intends to sell 5,000 shares of its common stock on May 30, with a total market value of approximately $560K. Kliman Gilb
Is Glaukos (NYSE:GKOS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $130
Citi analyst Joanne Wuensch maintains $Glaukos(GKOS.US)$ with a buy rating, and adjusts the target price from $120 to $130.According to TipRanks data, the analyst has a success rate of 62.2% and a tot